TITLE

Appendiceal Cancer and Peritoneal Carcinomatosis: A Report of 29 Cases

AUTHOR(S)
Esquivel, Jesus; Merriman, Barry; Davis, Sallie; Manning, Darrell
PUB. DATE
August 2006
SOURCE
American Surgeon;Aug2006, Vol. 72 Issue 8, p714
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Peritoneal surface malignancies of appendiceal origin arise from a perforated neoplasm with gradual expansion of the tumor within the abdomen. We report our experience with 29 patients. Between February 2000 and November 2004, 29 patients were classified into one of three groups based on the features of their peritoneal dissemination. Group I included those with extracellutar mucin with little cellular atypia (disseminated peritoneal adenomucinosis/low-grade mucinous adenocarcinomas). Group 2 included those with peritoneal mucinous carcinomatosis/high-grade mucinous adenocarcinomas, and Group 3 included those with nonmucinous carcinomatosis. There were 17 patients in Group 1, 9 in Group 2, and 3 in Group 3. The majority had cytoreductive surgery and intraperitoneal chemotherapy. There were no operative deaths. Mean follow-up was 21 months. Median survival for Groups 1 and 2 has not been reached. Group 3 patients were more likely to die than Group 1 patients, with a hazard ratio of 48.0 (P = 0.001), and Group 2 patients with a hazard ratio of 7.8 (P = 0.029). Median survival for Group 3 was 5 months. These data add to the growing evidence that supports cytoreductive surgery and intraperitoneal chemotherapy in a selected group of patients. Those with mucinous peritoneal dissemination are more likely to benefit from this approach. It appears that in patients with nonmucinous carcinomatosis, the biology of the tumor predicts their outcome.
ACCESSION #
21879601

 

Related Articles

  • Bypass of Tumor Drug Resistance by Antivascular Therapy. Preise, Dina; Mazor, Ohad; Koudinova, Natalia; Liscovitch, Mordechai; Scherz, Avigdor; Salomon, Yoram // Neoplasia;Nov/Dec2003, Vol. 5 Issue 6, p475 

    Multidrug resistance (MDR) presents a major obstacle for the successful chemotherapy of cancer. Its emergence during chemotherapy is attributed to a selective process, which gives a growth advantage to MDR cells within the genetically unstable neoplastic cell population. The pleiotropic nature...

  • The management of peritoneal surface malignancy of colorectal cancer origin. Tentes, A. A. K. // Techniques in Coloproctology;Nov2004 Supplement 1, Vol. 8, ps39 

    Colorectal carcinomas are predominantly spread malignancies. Peritoneal carcinomatosis frequently associates colorectal carcinomas. The tumour grade, the completeness of cytoreduction, the tumour volume, the presence of distant metastases, prior surgery score and the extent of peritoneal...

  • HIFU and Chemotherapy Synergistic Inhibitory Effect on Dunning AT2 Tumour-Bearing Rats. Curiel, Laura; Paparel, Philipe; Chesnais, Sabrina; Gelet, Albert; Chapelon, Jean-Yves // AIP Conference Proceedings;2005, Vol. 754 Issue 1, p191 

    Since there is no 100% satisfactory treatment for localized prostate cancer in patients presenting symptoms representing a poor prognosis (stage T3, high Gleason score, PSA level greater than 15 ng/ml, etc.), this study aimed to evaluate the therapeutic and synergistic inhibition effects of...

  • Bevacizumab.  // Reactions Weekly;9/1/2007, Issue 1167, p8 

    The article presents a case study of a 53-year old man with adenocarcinoma of the colon and has developed nasal septum perforation and fusariosis during treatment with bevacizumab for unresectable lung progression. The man started an LV5FU2 chemotherapy regimen and afterwards reported occasional...

  • Monoclonal gammopathy of undetermined significance (MGUS) in patients with solid tumors: effects of chemotherapy on the monoclonal protein. Anagnostopoulos, Athanasios; Galani, Eleni; Gika, Dimitra; Sotou, Danai; Evangelopoulou, Aikaterini; Dimopoulos, Meletios // Annals of Hematology;Oct2004, Vol. 83 Issue 10, p658 

    The aim of this study was to assess the effect of systemic chemotherapy on the monoclonal protein levels of patients with solid tumors who also have a monoclonal gammopathy of undetermined significance (MGUS). All patients with solid tumors who were referred to our department for consideration...

  • Effects of the proteasome inhibitor bortezomib alone and in combination with chemotherapy in the A549 non-small-cell lung cancer cell line. Mortenson, Melinda M.; Schlieman, Michael G.; Virudachalam, Subbulakshmi; Bold, Richard J. // Cancer Chemotherapy & Pharmacology;Oct2004, Vol. 54 Issue 4, p343 

    Background. Non-small-cell lung cancer (NSCLC) has a poor prognosis. Despite advances in therapy, survival has improved only slightly. The 26S proteasome regulates multiple cellular processes through degradation of ubiquitin-tagged proteins. The proteasome inhibitor, bortezomib (Velcade,...

  • New chemotherapeutics in malignant mesothelioma: effects on cell growth and IL-6 production. McLaren, Blair R.; Robinson, Bruce W. S.; Lake, Richard A.; McLaren, B R; Robinson, B W; Lake, R A // Cancer Chemotherapy & Pharmacology;Jun2000, Vol. 45 Issue 6, p502 

    Purpose: The benefits of chemotherapy can be assessed in terms of tumour shrinkage, prolongation of life or simply palliation of symptoms. In the study reported here, in vitro correlates of these parameters were sought as a rational guide to the choice of newer agents in the...

  • A phase I, dose-finding study of irinotecan (CPT-11) short i.v. infusion combined with fixed dose of 5-fluorouracil (5-FU) protracted i.v. infusion in adult patients with advanced solid tumours. Sastre, Javier; Paz-Ares, Luis; Carcas, Antonio; Alfonso, Rosario; Grávalos, Cristina; Frías, Jesus; Guerra, Pedro; Pronk, Linda; Cortés-Funes, Hernán; Díaz-Rubio, Eduardo; Grávalos, Cristina; Frías, Jesus; Cortés-Funes, Hernán; Díaz-Rubio, Eduardo // Cancer Chemotherapy & Pharmacology;May2005, Vol. 55 Issue 5, p453 

    Purpose: Irinotecan (CPT-11) and 5-fluorouracil (5-FU) are effective cytotoxic agents in the treatment of solid tumours. Continuous i.v. infusion (CI) of 5-FU is significantly more active and better tolerated than bolus i.v. 5-FU. This phase I pharmacokinetic and clinical study evaluated...

  • Phase II clinical study of gemcitabine in the treatment of patients with advanced nasopharyngeal carcinoma after the failure of platinum-based chemotherapy. Li Zhang; Yang Zhang; Pei-Yu Huang; Fei Xu; Pei-Jian Peng; Zhong-Zhen Guan // Cancer Chemotherapy & Pharmacology;Jan2008, Vol. 61 Issue 1, p33 

    This study was designed to evaluate the anti-tumor activity and toxicity profile of gemcitabine in the treatment of patients with advanced nasopharyngeal carcinoma (NPC) who had been pretreated with platinum-based chemotherapy. This is an open label, single arm phase II trial. All patients were...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics